Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C17H19N5S and a molecular weight of approximately 325.43 g/mol[3][5]. It belongs to the class of organic compounds known as 2,4,5-trisubstituted thiazoles[3]. The molecule has been studied as an experimental agent and is not approved for clinical use in any country[3]. Its primary mechanism of action is inhibition of cyclin-dependent kinase 2 (CDK2), an enzyme involved in cell cycle regulation. In biochemical assays it demonstrates inhibitory activity against CDK2 with IC50 values in the low nanomolar range (IC50 ≈ 220 nM; Ki ≈ 251 nM)[3][4]. There are no reported clinical indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-N',N'-dimethyl-benzene-1,4-diamine.